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Abstract
Background: Leishmaniasis is a spectrum of diseases with great relevance to public health. Conventional diagnostic
methods are time consuming, needing trained personnel. A robust, rapid and cost effective diagnostic test is
warranted for on-time diagnosis and field application.
Methods: We have developed a loop mediated isothermal amplification (LAMP) assay with primers (n = 6) based on
Leishmania donovani kDNA for detection of Leishmania infection, using a closed tube to prevent cross-contamination.
The assay was used to detect Leishmania infection in biological samples obtained from patients of visceral
leishmaniasis (VL), post kala-azar dermal leishmaniasis (PKDL) and cutaneous leishmaniasis (CL).
Results: The assay was positive for L. donovani, L. tropica and L. major parasites, with the highest sensitivity
towards L. donovani (1 fg DNA). The high sensitivity of the assay for detection of L. donovani was reflected in its
ability to detect parasite DNA within 30 min of amplification time with a threshold detection limit of ≥25 copies
per reaction. The assay detected parasite in 64 of 66 VL blood samples (sensitivity, 96.9%; 95% CI: 89.6-99.2%), 15
of 15 VL bone marrow aspirate samples (sensitivity, 100%; 95% CI:79.6-100%), 65 of 67 PKDL tissue biopsy samples
(sensitivity, 97%; 95% CI:89.7-99.2%). The assay was evaluated in a few cases of CL wherein it was found positive
in 8 of 10 tissue biopsies (sensitivity, 80%; 95% CI: 49-94.3%). The assay was negative in all control blood (n = 76)
and tissue biopsy (n = 24) samples (specificity, 100%; 95% CI: 96.3-100%). Further, the assay was evaluated for its
utility in assessment of cure in treated VL and PKDL patients. The assay detected parasite DNA in 2 of 20VL blood
samples and 2 of 21 PKDL tissue samples. Out of 4 cases that were positive for parasite DNA at post treatment
stage, 2 patients (1VL and 1 PKDL) returned with relapse.
Conclusions: The study demonstrated a Leishmania genus specific closed tube LAMP assay for reliable and rapid
molecular diagnosis of VL and PKDL with potential for application in assessment of cure.
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Background
Leishmaniasis, a group of diseases caused by protozoan
parasite Leishmania is transmitted to humans by the bite
of infected phlebotomine female sandflies. The disease is
endemic in about 98 countries, affecting 12 million
people worldwide. Clinical manifestations include cuta-
neous leishmaniasis (CL), mucocutaneous leishmaniasis
(MCL) to the deadly visceral leishmaniasis (VL). VL
mostly prevalent in tropical regions is caused by the par-
asites of L. donovani complex. In 2014, more than 90%
of new cases of VL reported to WHO occurred in six
countries: Brazil, Ethiopia, India, Somalia, South Sudan
and Sudan [1]. Post kala-azar dermal leishmaniasis (PKDL)
is a neglected complication of VL, characterized by macu-
lar, maculopapular and nodular lesions in a patient who
has recovered from VL. In India and Bangladesh, PKDL is
reported in 5-15% of patients treated for VL, usually after
an interval of a few months to several years [2, 3], however
in Sudan 50-60% of VL cases develop PKDL within a few
weeks of treatment [4]. The need to identify persons af-
fected with PKDL and treat them as a part of VL control
programs have been emphasized since PKDL patients are
considered as an important reservoir for the parasite
during inter-epidemic periods of VL [4]. In India, CL is pri-
marily endemic in the western Thar region of Rajasthan,
particularly in Bikaner, where L. tropica is the major causa-
tive agent [5].
Microscopic examination of tissue smears is consid-
ered as the gold standard for the definitive diagnosis of
VL and PKDL that suffers from low sensitivity. The sen-
sitivity of microscopy for VL ranges from 93-99% for
spleen aspirate to 53-86% for bone marrow, and 53-65%
for lymph node aspirates [6] while for PKDL diagnosis it
is higher for nodular cases (67-100%) compared to papu-
lar (36-69%) or macular (7-33%) cases [7]. Serological
methods (rK39 strip test, enzyme-linked immunosorbent
assay, direct agglutination test etc.) are highly sensitive,
however, fail to distinguish between past and present in-
fections hence are not conclusive for PKDL diagnosis
[8–11]. In last several years advances in the polymerase
chain reaction (PCR) based methods have been intro-
duced for diagnosis of leishmaniasis [12–15]. Several PCR
protocols have been developed for detection of Leish-
mania parasite, such as triplex PCR [16], multiplex PCR
[17], restriction fragment length polymorphism (RFLP)
analysis and nested PCR [18]. Quantitative Real-time PCR
(Q-PCR) has emerged as a highly sensitive tool for VL
and PKDL diagnosis with simultaneous quantification of
the parasite burden [19–22]. However, these assays are
not used for routine diagnosis of Leishmania infection as
these require of well equipped laboratory facilities along
with technical expertise.
Loop-mediated isothermal amplification (LAMP) assay,
a method to amplify DNA with rapidity and high
specificity under isothermal conditions, has emerged as an
efficient tool in the field of diagnostics [23]. LAMP assay
is rapid and cost effective as compared to PCR, offering
improved sensitivity and a higher tolerance for inhibitors
present in a number of clinical samples [24, 25]. Shorter
reaction time with visual judgment of positivity without
requiring sophisticated equipments makes it an attractive
diagnostic method for field application.
Although, a few studies employing LAMP assay to diag-
nose Leishmania infection are known [26–32] however,
these assays are limited in their utility because of the false
positivity due to cross contamination [29], or prolonged
reaction time [31] or the use specialized equipment [32].
Here, we have developed a LAMP assay based on kineto-
plast minicircle DNA (kDNA) of L.donovani for reliable
and rapid diagnosis of Leishmania infection in a closed




DNA from different Leishmania spp. including L. donovani
AG83 (MHOM/IN/83/AG83), L. major ASKH (MHOM/
SU/73/5ASKH) and L. tropica WR 683 (MHOM/ SU/58/
OD) were used in the study. All parasite cultures were
propagated in medium 199 supplemented with 25 mM
HEPES, pH 7.5 and 10% fetal calf serum. Parasites were
harvested in the late log phase and washed in phosphate-
buffered saline prior to DNA isolation using Promega
genomic wizard DNA isolation kit (Promega Corporation,
USA) according to the manufacturer’s instructions.
Clinical samples
VL and PKDL patients originating from Bihar and report-
ing respectively to Departments of Medicine and Derma-
tology, Safdarjung Hospital, New Delhi, were included in
this study. The patients with characteristic symptoms of
VL (fever, hepatosplenomegaly, anemia and leucopenia)
and PKDL (on clinico-histopathological observations) who
were positive by rK39 strip test were included in this study.
All the cases were confirmed by Q-PCR assay [21]. Per-
ipheral blood (0.5 ml from 66 cases) and bone marrow
aspirate BMA (100 μl from 15 cases) were collected
from VL patients while tissue biopsy (4-6 mm punch
biopsy from 67 cases) were collected from PKDL patients
at pre-treatment stage. VL and PKDL samples used in this
study included those reported earlier [29] in addition to
new cases that reported thereafter. Tissue biopsy sample
DNA of Q-PCR [5] confirmed CL (n = 10) cases who
reported to Department of Skin, STD &Leprosy, S.P.
Medical College, Bikaner (Rajasthan), India, were also
included in this study. Blood (0.5 ml) samples from
healthy volunteers (endemic n = 24; non-endemic, n = 38),
malaria patients (n = 7) and tuberculosis patients (n = 7) as
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well as tissue biopsy (4-6 mm punch biopsy) samples from
leprosy patients (n = 18) and cases of fungal diseases
(Sporotrichosis or Pityriasis lichenoides chronica) (n = 6)
were included as controls.
DNA isolation from clinical samples
Blood and bone marrow sample was collected in heparin-
ized tubes. DNA extraction was performed using QIAamp
DNA Blood mini kit (Qiagen, Germany) according to man-
ufacturer’s instructions. DNA was isolated from 200 μL of
blood and eluted in 50 μL nuclease free water. In case of
BMA sample, 100 μL of BMA was used and eluted in
100 μL nuclease free water. In order to achieve maximum
yield in BMA samples, digestion was performed overnight
with proteinase K in lysis solution [29]. Punch biopsy
(4-6 mm) sample was taken under sterile conditions
from the dermal lesions of PKDL and CL cases in NET
buffer (150 mM NaCl, 15 mM Tris-HCl pH 8.30 and
1 mM EDTA). DNA was extracted and eluted in 100 μl
of nuclease free water using QIAamp DNA Tissue kit
according to manufacturer’s instructions.
Design of LAMP primers
Sets of outer forward primer (F3), outer backward primer
(B3), forward inner primer (FIP) and backward inner primer
(BIP) targeting regions of L. donovani kDNA sequence
(GenBank accession no. Y11401.1) were designed using the
online Primer Explorer V4 software (Eiken Chemical Co.
Ltd., Japan, http://primerexplorer.jp/elamp4.0.0/index.html).
Loop primers [Forward loop primer (FLP) and Backward
loop primer (BLP)] were designed manually. Three primer
sets were tested and the primer set giving highest sensitivity
was used in the study. The primer set used is shown in
Fig. 1.
Fig 1 Primers for LAMP assay. Primers for LAMP assay were designed for amplification of Leishmania DNA from L. donovani kinetoplast minicircle
sequence (Acession no Y11401) using Primer Explorer V4 software. A total of six primers (F3, B3, FIP, BIP, FLP and BLP) were designed for the LAMP assay
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Cloning and sequencing of LAMP amplicon from
Leishmania spp
The LAMP amplicon from kDNA minicircle from Leish-
mania spp, was amplified using F3 and B3 primers. The
PCR reaction mixture of final volume 50 μl contained 50
pmol of F3 and B3 primers, 10 ng of parasite DNA (L.
donovani, L. major and L. tropica), 200 μM each of dNTP
mix, 2 mMMgSO4, and 1 U Platinum Taq DNA polymer-
ase (Invitrogen, USA) in 1× Taq buffer. PCR reaction con-
ditions included initial denaturation at 94 °C for 2 min.,
followed by 35 cycles of 94 °C for 15 s., 62 °C for 30 s.,
68 °C for 30 s., and final extension at 68 °C for 2 min. The
PCR amplicon (200 bp) along with 100 bp DNA ladder
were resolved by 2% agarose gel electrophoresis. PCR
amplicons were purified and ligated into pGEMT easy
cloning vector (Promega Corporation, USA) following
manufacturer's instructions. Recombinant plasmids were
characterized using restriction enzyme EcoRI (MBI
Fermentas, USA) for insert fall out (200 bp). The ampli-
cons were cloned into pGEMT vector and transformed
into E.coli DH5α strains. The positive clones were
screened by blue and white selection on X-gal and IPTG
containing Luria-Bertani agar plates. The white colonies
were selected and sequenced using T7/SP6 primers on
Automated Sequencer 3730 Version 3.0 (ABI PRISM).
LAMP assay
The LAMP reaction was performed in 25 μl of reaction
mixture containing 40 pmol each of FIP and BIP
primers, 5 pmol each of F3 and B3 primers,20 pmol each
of the FLP and BLP, 1.4 mM of each deoxynucleoside
triphosphate, 0.8 M betaine, 20 mM Tris-HCl, pH 8.8,
10 mMKCl, 10 mM (NH4)2SO4, 8 mM MgSO4, 0.1%
TritonX-100, 8 units of Bst DNA polymerase large Frag-
ment (New England Biolabs, Ipswich, MA), and 2 μl of
DNA from parasites and clinical specimen. Before start-
ing the reaction, 1 μl of diluted (1/10) SYBR Green I
(Molecular Probes, Eugene, OR, USA) was placed on the
inner side of the cap of PCR tube. The tube was closed
and incubated at 65 °C for 30 min in a heating block.
On completion of reaction, the tube was centrifuged to
allow mixing of SYBR Green I with the amplified prod-
uct. All positive samples produced a green colour almost
immediately upon mixing of SYBR Green I, while the
negatives remained orange. The samples were tested in a
batch of 24 including clinical samples from patients of
Leishmaniasis and other diseases. In every batch, mini-
mum 2 DNA samples from healthy individuals and one
blank control in which DNA was replaced by water was
used as negative and reagent control, respectively.
Quantitative Real Time PCR (Q-PCR) assay
SYBR Green I based Leishmania genus specific Q-PCR
was performed using F3 and B3 primers using the
reaction conditions as described previously [21]. A 10 μl
of the PCR reaction was performed, consisting of 1X
SYBR Green I PCR Master mix (Applied Biosystems,
USA), 5 pmol forward primer F3, 5 pmol reverse primer
B3, and 1 μl sample DNA. The cycling parameters were
50 °C for 2 min, 95 °C for 10 min, and 40 cycles of 95 °C
for 15 s and 60 °C for 1 min. A standard curve was con-
structed using 10-fold serially diluted kDNA plasmid
corresponding to 108 to 103 copies per reaction. A
threshold cycle value (Ct) was calculated for each sample
by determining the point at which the fluorescence
exceeded the threshold limit. All the reactions were per-
formed in triplicate.
Results
Cloning and sequence analysis of kDNA minicircle
PCR-amplification of kDNA from total DNA isolated
from L. donovani, L. major and L. tropica, using F3 and
B3 primers yielded the product of 200 bp size of variable
intensity (Fig. 2a). The corresponding amplicons were
cloned, sequenced and subjected to multiple sequence
alignment. Data revealed 100% sequence identity in case
of L. donovani, 97% in case of L. major and 96.5% in
case of L. tropica (Fig. 2b).
Determination of kDNA copy number in Leishmania spp.
using Q-PCR
For evaluation of differences in copy number of kDNA
minicircle in different Leishmania spp, a standard curve
was established with serially diluted known number of
kDNA plasmid copies (103 to 108) from L. donovani. The
mean standard curve was linear over 6 log range with cor-
relation coefficient (r2) of 0.991 (Fig. 2c). A negative con-
trol (water instead of template DNA) with each PCR assay
was included for stringent measures. Q-PCR assay with
parasite DNA from Leishmania spp. revealed that the
copy number of kDNA varied from 500-10000 copies in L.
donovani, 10-20 copies in L. tropica and 1-10 copies in L.
major.
Analytical sensitivity and specificity of the LAMP assay
with Leishmania spp. DNA
The assay was performed with DNA from L. donovani,
L. tropica and L. major parasites and found positive in
all. Specificity of the assay was evaluated using DNA
from microorganisms causative of the common infectious
diseases prevalent in India such as Plasmodium spp.,
Mycobacterium leprae and M. tuberculosis which were all
observed to be negative. Further, the analytical sensitivity
of the LAMP assay was determined by serial dilution of
parasite DNA (10 ng – 1 fg) from different Leishmania
spp. The sensitivity of LAMP assay was higher towards
L. donovani (up to 1 fg parasite DNA) and L. tropica
(up to 1 pg parasite DNA) as compared to L. major (up
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to 100 pg parasite DNA), (Fig. 3a-c). These results cor-
related well with the intensity of PCR product obtained
with L. donovani, L. tropica and L. major (Fig. 2a). The
sensitivity of the assay was also determined using DNA
isolated from L. donovani parasites (105 to 10) spiked
healthy blood (200 μl) and,the LAMP assay could de-
tect the Leishmania DNA up to 10 parasites dilution.
Comparison of detection limits of LAMP and Q-PCR assays
To assess the threshold detection limit for LAMP and
Q-PCR assays for L. donovani, the two assays were per-
formed with serial dilutions of kDNA plasmid. The
LAMP assay was found positive for ≥25 copies per re-
action whereas Q-PCR assay was positive for ≥10 cop-
ies per reaction.
Sensitivity and specificity of the LAMP assay in clinical
samples
The clinical applicability of the LAMP assay was assessed
using DNA isolated from the clinical samples including
blood from cases of VL tuberculosis, malaria and tissue
biopsy from cases of PKDL, CL and leprosy. The assay
was positive for VL, PKDL and CL samples and negative
for all others (Fig. 3d). The LAMP assay was positive in 64
out of 66 confirmed cases of VL using DNA from blood
samples, giving a sensitivity of 96.9% (95% CI, 89.6-99.2%).
In comparison, the microscopy was positive in 42 of 66
(63.6%) cases. The assay was positive in all (n = 15) BMA
samples of confirmed VL cases at pre-treatment stage giv-
ing sensitivity of 100% (95% CI, 79.6-100%). LAMP assay
detected parasite DNA in 65 out of 67 confirmed PKDL
cases using tissue biopsy, giving sensitivity of 97% (95%
CI, 89.7-99.2%) while microscopy was positive in only 21
out of 67 (31.3%) cases. When evaluated in CL cases, the
assay was found positive in 8 of 10 cases giving sensitivity
of 80% (95% CI: 49-94.3%). The assay was negative in all
(n = 100) controls (blood, n = 76; tissue, n = 24) giving a
specificity of 100% (95% CI, 96.3 -100%). These results re-
vealed a high sensitivity (Table 1) and specificity (Fig. 3d)
of LAMP assay for diagnosis of VL and PKDL.
Assessment of novel LAMP assay as test of cure
To evaluate the applicability of LAMP assay for assess-
ment of cure in VL and PKDL, 20 cases of VL and 21
Fig 2 PCR amplification, multiple sequence alignment and standard curve plot. a PCR amplification of kDNA minicircle using parasite DNA
from L. donovani, L. major and L.tropica. Product of 200 bp size was obtained in all cases. b Multiple Sequence Alignment using CLUSTAL
OMEGA. The amplified kDNA sequences from L. donovani, L. tropica and L. major were sequenced and percentage identity analyzed using
Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/). Percent identity is shown in parenthesis. c Standard curve obtained with serially
diluted L. donovani kDNA plasmid. SYBR Green 1 based QPCR was carried out using F3 and B3 primers at each dilution. Graph shows Ct value
plotted at different copy number of kDNA
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cases of PKDL were examined 1-month post-treatment,
as reported in our earlier study employing Q-PCR (21,
33). When examined at post treatment stage, the VL
blood (2 of 20) samples and PKDL tissue (2 of 21) sam-
ples from the follow-up samples of the above patients
were found to be positive for parasite DNA both by
LAMP and QPCR assay. This confirmed that the LAMP
and Q-PCR assay correlated well for detection of para-
site in clinical samples. Out of the four cases (2 VL and
2 PKDL) that were positive for parasite at post-
treatment stage, two patients (1 VL and 1 PKDL) ap-
peared with relapse.
Discussion
An effective control of VL and PKDL warrants reliable,
rapid and cost effective diagnostic tools. Diagnosis by
microscopy is a classical confirmatory test that suffers
from low sensitivity. PCR based diagnosis has remained
a definitive breakthrough, however, it is a time consuming
process and needs sophisticated instruments. A diagnostic
test to be prospected as a point-of-care test and to be used
in the field settings must qualify two basic criteria: a) high
sensitivity and specificity & b) economical and easy to per-
form. The widely prevalent rK39 strip test as a diagnostic
test is adequate for VL but is of limited value for PKDL
diagnosis as a positive result produced may occur due to
antibodies persisting due to past episode of VL. Identifica-
tion of PKDL patients is important to VL Elimination Pro-
gram [33] as they serve as durable reservoirs during inter-
epidemic episodes, hence, a faster and reliable molecular
assay for accurate PKDL diagnosis is warranted. Among
molecular diagnostic methods LAMP has emerged as a
Fig 3 Sensitivity and specificity of LAMP assay. Sensitivity of LAMP assay using serial dilutions of DNA (1 ng–1 fg) from a L. donovani b L. tropica
and c L. major. d Specificity of LAMP assay for diagnosis of VL, PKDL and CL in clinical samples
Table 1 Sensitivity of the LAMP assay for diagnosis of VL, PKDL and CL
Sample Cases tested for LAMP (confirmed by Q-PCRab) Cases positive for LAMP LAMP Sensitivity (95% Confidence Interval)
VL (Blood) 66a 64 96.9% (89.6 - 99.2%)
VL (BMA) 15a 15 100% (79.6 - 100%)
PKDL (Tissue) 67a 65 97% (89.7 - 99.2%)
CL (Tissue) 10b 8 80% (49 - 94.3%)
aReference no. 20
bReference no. 21
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promising test and has been successfully applied in
diagnosis of various protozoan diseases like African
trypanosomiasis [34], malaria [35], giardiasis [36],
cryptosporidiosis [37] and leishmaniasis [26–32]. The
closed tube LAMP assay reported here has the poten-
tial as a reliable point of care test for diagnosis of
PKDL, with minimal risk of cross-contamination. The
LAMP assay using 4 primers that we reported earlier
for rapid diagnosis of VL and PKDL [29], was species-
specific for L.donovani, being negative for L.infantum,
L. tropica, and L. major. The novel 6 primer LAMP
assay reported here is superior to the previous one, be-
ing faster and more sensitive for detection of L. dono-
vani. Further, it is applicable for diagnosis of CL since
it detects L. tropica and L. major. The assay had the
highest sensitivity towards L. donovani, being capable
to detect 1 fg parasite DNA per reaction that corresponded
to less than 1 parasite. The sensitivity and specificity of our
LAMP assay is high with a short amplification time. Evalu-
ation of the test in small number of cases of CL gave a sen-
sitivity of 80%; however, a study is warranted in large
number of cases to explore its utility for diagnosis of CL.
We sought to address whether the lower sensitivity of
detection in L. major and L. tropica was due to differ-
ence in sequence or copy number of the target kDNA. It
is well known that all copies of kDNA within a parasite
kinetoplast are not identical and variations in the target
minicircle sequences are observed. Here, a base differ-
ence in the sequence of the chosen minicircle amplicon
at the forward primer site in case of L. major DNA was
observed. This may explain the reduced sensitivity of the
assay to detect L. major spp. Q-PCR assay showed varia-
tions in minicircle copies from 500-10000 in L. donovani
strains, 10-20 copies in L. tropica and 1-10 copies in L.
major, although, estimates of the copy number for L.
major is not conclusive due to variation in L. major tar-
geted sequence at forward Q-PCR primer site.
In the present study we have chosen Q-PCR (21) as
the reference test as it is reported as one of the most
sensitive molecular assay to detect parasite DNA in clin-
ical samples, therefore, we compared the threshold detec-
tion limit of kDNA copies by LAMP vs. Q-PCR assay.
The threshold copy number detection limits for LAMP
and Q-PCR assays were determined as ≥25 copies and
≥10 copies, respectively. The comparative detection limits
for the two assays were similar to that reported for detec-
tion of orf virus [38]. Thus, with the sensitivity compar-
able to Q-PCR (both detects up to 1 fg DNA), LAMP
assay can undoubtedly be volunteered as an efficient tool
for diagnosis of VL and PKDL as it is simpler, faster and
easy to perform. In addition, LAMP assay efficiently de-
tected parasite DNA in the same VL (n = 2/20) and PKDL
(n = 2/21) cases at post-treatment stage which were de-
tected positive for parasite DNA by Q-PCR as reported
earlier [21, 39]. Close agreement in the results of LAMP
and Q-PCR assays at post-treatment stage highlights the
utility of LAMP assay as a point-of-care test for assess-
ment of cure of VL and PKDL cases, though a detailed
evaluation of the assay in a large number the patients is
required to appraise its prognostic efficacy. The less inva-
sive methods of sample collection like finger prick blood
sampling and direct LAMP assays avoiding the DNA iso-
lation steps are desirable for field based diagnosis.
Despite the numerous advantages, LAMP assay faces a
major issue of product cross-contamination that limits
its application in the field. In the past, LAMP assays using
wax dye capsule method, calcein or hydroxyl-napthol blue
metal indicators at the start of the reaction were intro-
duced to prevent opening of lid after amplification [40].
Our closed tube LAMP assay using SYBR green I is a fur-
ther improvement as this indicator gives better sensitivity
and clarity in visualization of the results.
Conclusions
The LAMP assay developed in the present study can de-
tect DNA from L. donovani, L. tropica and L. major par-
asites; hence it is applicable for the rapid and reliable
diagnosis of VL, PKDL and CL. The method is easy to
perform, cost-effective and rapid with much reduced re-
action time of 30 mins. Above all, the need to open the
tube for adding SYBR Green I for detection of amplifica-
tion is not required, ruling out the occurrence of false
positive results. All the above factors justify the use of
the presently defined LAMP assay in large epidemiologic
studies to be performed in field settings. To conclude, the
LAMP assay developed by us falls in the category of high
performance result oriented tests having rapid turn-
around time with a minimal chance of error. Thus, we
propose that the reformed LAMP assay reported here
may be exploited as a point of care test for diagnosis as
well as for assessment of cure for both VL and PKDL.
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